Which has the lower trailing P/E, ARQT or CDNA?

CDNA has the lower trailing P/E: ARQT trades at 116.74 and CDNA at 32.80. P/E is one valuation measure and does not by itself establish which business is cheaper.

Is ARQT or CDNA more profitable?

CDNA runs the higher net margin — ARQT at 6.15% versus CDNA at 24.23%.

How have ARQT and CDNA total returns compared?

Over the past 5 years, ARQT delivered -0.28% and CDNA delivered 1.33% annualized total return. Past performance doesn't predict future results.

Arcutis Biotherapeutics, Inc. (ARQT) vs CareDx, Inc (CDNA)

A side-by-side comparison of Arcutis Biotherapeutics, Inc. and CareDx, Inc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ARQT

Arcutis Biotherapeutics, Inc.

$3.04B

$24.34HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT

CDNA

CareDx, Inc

$3.51B

$67.94HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT

Total return — ARQT vs CDNA

growth of $100 · dividends reinvested · last 7y

ARQT +15.4% (+2.1%/yr)CDNA +191.6% (+16.5%/yr)CDNA compounded faster over this window

ARQT CDNA

ARQT vs CDNA: by the numbers

•CDNA is the larger company ($3.51B vs $3.04B market cap).
•CDNA trades at the lower trailing earnings multiple (32.80 vs 116.74 P/E), one valuation lens rather than an overall verdict.
•CDNA converts more revenue to profit (24.23% vs 6.15% net margin).

Metrics side by side

Valuation

Metric	ARQT	CDNA
P/E ratio	116.74	32.80
Forward P/E	48.96	56.72
P/S ratio	6.56	7.67
P/B ratio	13.80	8.26
EV / EBITDA	83.99	203.14
FCF yield	1.29%	2.42%

Profitability

Metric	ARQT	CDNA
Gross margin	91.14%	70.58%
Operating margin	-3.25%	-0.92%
Net margin	6.15%	24.23%
ROE	12.93%	26.08%
ROIC	9.95%	-0.93%

Growth (annualized)

Metric	ARQT	CDNA
Revenue CAGR (5Y)	N/A	12.56%
Total return CAGR (5Y)	-0.28%	1.33%

Frequently asked

Which has the lower trailing P/E, ARQT or CDNA?: CDNA has the lower trailing P/E: ARQT trades at 116.74 and CDNA at 32.80. P/E is one valuation measure and does not by itself establish which business is cheaper.
Is ARQT or CDNA more profitable?: CDNA runs the higher net margin — ARQT at 6.15% versus CDNA at 24.23%.
How have ARQT and CDNA total returns compared?: Over the past 5 years, ARQT delivered -0.28% and CDNA delivered 1.33% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ARQT analysis Full CDNA analysis Interactive comparison tool

Dig into the metrics

Arcutis Biotherapeutics P/E ratio CareDx P/E ratio Arcutis Biotherapeutics ROE CareDx ROE Arcutis Biotherapeutics operating margin CareDx operating margin Arcutis Biotherapeutics revenue growth CareDx revenue growth Arcutis Biotherapeutics free cash flow CareDx free cash flow

Arcutis Biotherapeutics & CareDx appear in these rankings

Highest ROE Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.